GleamWall
中文EN

NAGE Niagen Bioscience, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1386570 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.9%
TTM net income YoY-49.9%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR13.6%
Net income 3-yr CAGR—

Margins

Gross margin63.9%
Operating margin3.9%
Net margin8.4%
FCF margin—
EBITDA margin4.3%

Returns

ROE13.3%
ROA9.9%
ROIC (approx.)44.3%
Asset turnover1.18x

Leverage & solvency

Liabilities / assets23.6%
Debt / equity0.00x
Current ratio5.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$27.19M$29.79M$31.47M$33.84M$33.99M$31.12M$30.48M$29.12M
Cost of revenue$10.09M$10.47M$11.50M$12.13M$12.06M$10.89M$11.15M$10.93M
Gross profit$17.11M$19.31M$19.98M$21.70M$21.93M$20.23M$19.33M$18.20M
R&D expense$1.80M$1.51M$1.48M$1.71M$1.79M$1.57M$1.26M$1.31M
SG&A expense$8.18M$6.97M$7.24M$7.48M$7.13M$7.27M$5.18M$1.05M
Operating income-$1.59M$700,000$1.58M$4.09M$4.24M$3.19M$4.77M$7.11M
Pretax income-$1.17M$1.07M$6.74M$4.42M$4.80M$3.74M$5.23M$7.48M
Income tax$0$106,000$417,000$292,000$222,000$128,000$168,000$305,000
Net income-$1.17M$963,000$6.32M$4.13M$4.58M$3.61M$5.06M$7.18M
EBITDA-$1.47M$817,000$1.69M$4.22M$4.39M$3.34M$4.93M$7.26M
EPS (basic)-0.010.010.08—0.060.050.07—
EPS (diluted)-0.010.010.07—0.050.040.06—
Weighted avg. shares (diluted)79.15M82.50M84.57M—86.62M86.24M83.23M—
Balance sheet
Cash & equivalents$69.51M$66.74M$66.55M$64.79M$64.29M$60.47M$55.62M$44.66M
Receivables$6.84M$8.58M$13.07M$9.74M$8.51M$9.66M$7.05M$7.77M
Inventory$20.52M$20.64M$24.02M$20.42M$18.79M$14.41M$11.19M$9.19M
Current assets$100.22M$97.79M$105.12M$96.81M$93.62M$86.68M$76.22M$64.10M
PP&E, net$1.22M$1.25M$1.30M$1.32M$1.50M$1.63M$1.66M$1.72M
Intangibles$5.14M$5.31M$5.49M$5.66M$246,000$284,000$322,000$359,000
Total assets$108.69M$106.59M$114.33M$106.41M$98.14M$91.53M$81.34M$68.28M
Current liabilities$16.91M$15.05M$22.82M$19.92M$22.71M$22.33M$20.84M$17.95M
Total liabilities$25.62M$24.06M$32.00M$29.87M$27.46M$27.33M$25.99M$22.18M
Shareholders' equity$83.07M$82.53M$82.33M$76.53M$70.68M$64.19M$55.34M$46.09M
Shares outstanding79.03M78.91M79.46M79.71M79.64M79.59M78.43M77.33M
Cash flow statement
Operating cash flow$2.62M$2.77M-$1.19M$679,000$3.69M$1.25M$7.88M$8.58M
Investing cash flow-$52,000-$92,000$5.25M-$101,000-$24,000-$135,000-$32,000-$69,000
Financing cash flow$196,000-$2.49M-$2.29M-$80,000$148,000$3.74M$3.10M$3.75M
Depreciation & amortization$115,000$117,000$116,000$139,000$157,000$158,000$158,000$151,000
Stock-based compensation$1.52M$1.72M$1.72M$1.75M$1.76M$1.49M$1.07M$752,000
Share buybacks$0$2.77M$2.35M$251,000$0$0$0—

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.